Frequencies for first 10,000 rows of drug2cl2 variable in nhamcsopd2005 dataset :

          ndc code #2 for medication #2 |      Freq.     Percent        Cum.
----------------------------------------+-----------------------------------
                        medicinal gases |          1        0.01        0.01
                   anesthetics, topical |          1        0.01        0.02
          sulfonamides and trimethoprim |          1        0.01        0.03
                            antifungals |          1        0.01        0.04
                     antianginal agents |          2        0.02        0.06
                antihypertensive agents |          1        0.01        0.07
                              diuretics |         14        0.14        0.21
                          beta blockers |         17        0.17        0.38
           alpha agonist/alpha blockers |         17        0.17        0.55
                        antidepressants |          1        0.01        0.56
                     cns, miscellaneous |          1        0.01        0.57
                         antidiarrheals |          3        0.03        0.60
        antispasmodics/anticholinergics |          1        0.01        0.61
                      vitamins/minerals |          8        0.08        0.69
repl/regs of electrolytes/water balance |          3        0.03        0.72
                     calcium metabolism |          1        0.01        0.73
                   estrogens/progestins |          2        0.02        0.75
               blood glucose regulators |          4        0.04        0.79
                         contraceptives |          1        0.01        0.80
                      vaccines/antisera |          9        0.09        0.89
              antiseptics/disinfectants |          1        0.01        0.90
                   dermatologics, misc. |          8        0.08        0.98
                       topical steroids |          1        0.01        0.99
                          acne products |          1        0.01        1.00
               dermatitis/antipruritics |          1        0.01        1.01
                     topical analgesics |         26        0.26        1.27
          skeletal muscle hyperactivity |         14        0.14        1.41
                        anticonvulsants |          1        0.01        1.42
         antineoplastics, miscellaneous |          1        0.01        1.43
      hormonal/biological response mod. |          4        0.04        1.47
                cycloplegics/mydriatics |          3        0.03        1.50
ocular anti-infective/anti-inflammatory |          1        0.01        1.51
              miscellaneous ophthalmics |          2        0.02        1.53
       vertigo/motion sickness/vomiting |         27        0.27        1.80
                         relief of pain |          1        0.01        1.81
                   analgesics, narcotic |          1        0.01        1.82
               analgesics, non-narcotic |          1        0.01        1.83
           antimigraine/other headaches |          2        0.02        1.85
                         antiarthritics |         68        0.68        2.53
                                  nsaid |         29        0.29        2.82
                           antipyretics |        100        1.00        3.82
   antitussives/expectorants/mucolytics |         19        0.19        4.01
                         antihistamines |         26        0.26        4.27
                          cold remedies |          4        0.04        4.31
        corticosteroid-inhalation/nasal |          4        0.04        4.35
                    pharmaceutical aids |         17        0.17        4.52
                          surgical aids |          1        0.01        4.53
                                      . |      9,547       95.47      100.00
----------------------------------------+-----------------------------------
                                  Total |     10,000      100.00

by Jean Roth , jroth@nber.org , 28 Mar 2016